ReviewCNS & neurological disorders drug targets2026
Research Prospects for mTOR in Neuroinflammation: A Bibliometric Analysis.
Review in CNS & neurological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Changing Paradigm of Neuroinflammation in Epilepsy: A Bibliometric Analysis from Microglial Activation to Gut-Brain Axis.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeuroinflammation is a key pathological process in neurological disorders, from acute injuries to chronic diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), and stroke. The mTOR pathway regulates neuroinflammation by influencing microglial activation, autophagy, and synaptic plasticity. To address the scarcity of systematic analyses in this growing field, our study employs bibliometric analysis to map the landscape, identify key themes and collaborations, and highlight therapeutic targets for future neurological research.
methodsA Web of Science search retrieved articles published up to 2024. Bibliometric analysis and visualization were conducted using VOSviewer, CiteSpace, Charticulator, and Microsoft Excel.
resultsA total of 509 articles were examined, showing a fluctuating increase in publications and citations. China had the highest output, and the Journal of Neuroinflammation was the most active journal. Mehan Sidharth emerged as a leading researcher. The most cited study was "HIF1α- dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells". Findings revealed strong links between neuroinflammation and AD, PD, and stroke, and highlighted mTOR inhibitors as promising therapeutic agents. DISCUSSION: Our analysis identified highly-cited works, current trends, emerging frontiers, and the significance of mTOR inhibitors. However, the comprehensiveness of our bibliometric approach may have been limited by the field's vast scope and by analytical disparities between CiteSpace and VOSviewer, potentially resulting in omissions.
conclusionThis study provides an overview of scientific progress on mTOR signaling and neuroinflammation, emphasizing its key role in disease mechanisms and suggesting directions for therapeutic innovation.
Indexed as
Identifiers
41510733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.